LOGIN  |  REGISTER
C4 Therapeutics
Chimerix

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results

October 21, 2025 | Last Trade: US$78.57 3.98 5.34

WARREN, N.J., Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, November 4, at 4:30 p.m. ET.

To access the call by phone, please click here to register, and you will be provided with dial-in details. To avoid delays, we recommend that participants dial in for the conference call 15 minutes before the start of the call. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days.

ABOUT PTC THERAPEUTICS, INC.

PTC is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on Facebook, X, and LinkedIn.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Jeanine Clemente
+1 (908) 912-9406
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page